Bio-Techne Zukünftiges Wachstum
Future Kriterienprüfungen 3/6
Bio-Techne wird ein jährliches Gewinn- und Umsatzwachstum von 23.5% bzw. 6.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 24.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.4% betragen.
Wichtige Informationen
23.5%
Wachstumsrate der Gewinne
24.05%
EPS-Wachstumsrate
| Life Sciences Gewinnwachstum | 15.2% |
| Wachstumsrate der Einnahmen | 6.7% |
| Zukünftige Eigenkapitalrendite | 15.42% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 22 Apr 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Feb 12
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Jan 08TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Nov 08TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)
Jul 28What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?
May 29Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Feb 27
Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges
Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 6/30/2028 | 1,426 | 266 | N/A | N/A | 5 |
| 6/30/2027 | 1,300 | 228 | 393 | 463 | 11 |
| 6/30/2026 | 1,225 | 196 | 261 | 269 | 12 |
| 12/31/2025 | 1,216 | 81 | 223 | 249 | N/A |
| 9/30/2025 | 1,217 | 78 | 224 | 251 | N/A |
| 6/30/2025 | 1,220 | 73 | 257 | 288 | N/A |
| 3/31/2025 | 1,209 | 132 | 221 | 265 | N/A |
| 12/31/2024 | 1,196 | 158 | 254 | 305 | N/A |
| 9/30/2024 | 1,172 | 151 | 245 | 303 | N/A |
| 6/30/2024 | 1,159 | 168 | 236 | 299 | N/A |
| 3/31/2024 | 1,154 | 203 | 251 | 307 | N/A |
| 12/31/2023 | 1,145 | 224 | 225 | 276 | N/A |
| 9/30/2023 | 1,144 | 247 | 215 | 258 | N/A |
| 6/30/2023 | 1,137 | 285 | 216 | 254 | N/A |
| 3/31/2023 | 1,124 | 271 | 233 | 274 | N/A |
| 12/31/2022 | 1,120 | 262 | 252 | 296 | N/A |
| 9/30/2022 | 1,118 | 292 | 285 | 333 | N/A |
| 6/30/2022 | 1,106 | 272 | 280 | 325 | N/A |
| 3/31/2022 | 1,076 | 225 | 302 | 345 | N/A |
| 12/31/2021 | 1,030 | 210 | 308 | 346 | N/A |
| 9/30/2021 | 985 | 177 | 295 | 335 | N/A |
| 6/30/2021 | 931 | 140 | 308 | 352 | N/A |
| 3/31/2021 | 848 | 184 | 225 | 275 | N/A |
| 12/31/2020 | 799 | 175 | 201 | 250 | N/A |
| 9/30/2020 | 760 | 248 | 179 | 231 | N/A |
| 6/30/2020 | 739 | 229 | 153 | 205 | N/A |
| 3/31/2020 | 755 | 187 | 170 | 216 | N/A |
| 12/31/2019 | 745 | 195 | 165 | 207 | N/A |
| 9/30/2019 | 734 | 93 | N/A | 183 | N/A |
| 6/30/2019 | 714 | 96 | N/A | 182 | N/A |
| 3/31/2019 | 703 | 121 | N/A | 191 | N/A |
| 12/31/2018 | 682 | 96 | N/A | 173 | N/A |
| 9/30/2018 | 661 | 128 | N/A | 165 | N/A |
| 6/30/2018 | 643 | 126 | N/A | 170 | N/A |
| 3/31/2018 | 619 | 112 | N/A | 156 | N/A |
| 12/31/2017 | 599 | 114 | N/A | 160 | N/A |
| 9/30/2017 | 577 | 73 | N/A | 162 | N/A |
| 6/30/2017 | 563 | 76 | N/A | 144 | N/A |
| 3/31/2017 | 541 | 74 | N/A | 129 | N/A |
| 12/31/2016 | 528 | 82 | N/A | 141 | N/A |
| 9/30/2016 | 517 | 101 | N/A | 138 | N/A |
| 6/30/2016 | 499 | 104 | N/A | 144 | N/A |
| 3/31/2016 | 482 | 105 | N/A | 145 | N/A |
| 12/31/2015 | 465 | 99 | N/A | 138 | N/A |
| 9/30/2015 | 456 | 107 | N/A | 135 | N/A |
| 6/30/2015 | 452 | 108 | N/A | 139 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: TECHDas prognostizierte Gewinnwachstum (23.5% pro Jahr) liegt über der Sparquote (3.4%).
Ertrag vs. Markt: TECHDie Erträge des Unternehmens (23.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (16.1% pro Jahr).
Hohe Wachstumserträge: TECHEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: TECHDie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11% pro Jahr).
Hohe Wachstumseinnahmen: TECHDie Einnahmen des Unternehmens (6.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: TECHDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.4%).
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/04/30 12:56 |
| Aktienkurs zum Tagesende | 2026/04/29 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Bio-Techne Corporation wird von 25 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Wasserman | Benchmark Company |